- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02770677
Modified Dantien Salee Yoga Training Program in Chronic Obstructive Pulmonary Disease Rehabilitation
August 14, 2019 updated by: Duangjun Phantayuth, Mahidol University
COPD patients will be recruited and assigned into one of each group: 1) Control group or 2) Yoga group.
In Yoga groups, subjected will be asked to participate in Modified Dantien Yoga training for 12 weeks (3 times/week, 60 min/time).
The subjects will be evaluated their pulmonary function, functional fitness performance, dyspnea score, and quality of life at baseline and after 12 wk training.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
12
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Bangkok
-
Bangkoknoi, Bangkok, Thailand, 10700
- Recruiting
- Faculty of Medicine, Siriraj Hospital
-
Contact:
- Arth Nana, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Stable COPD patients > or equal 6 weeks.
- Age > or equal 50-80 years.
- FEV1 > or equal 30% predicted after take bronchodilators drug.
- Resting SpO2 > or equal 90% room air.
- Did not pulmonary rehabilitation program before start the yoga
Exclusion Criteria:
- Subjects with musculoskeletal disorders, mental and neurological disorders, and acute coronary heart disease.
- Blood Pressure (systolic) > 180 mmHg.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control group
Control group will be asked to continue their normal daily life without Yoga training
|
|
|
Experimental: Yoga group
Yoga group will be exposed to Modified Dantien Salee Yoga Training Program for 12 weeks
|
The intervention aims to improve pulmonary function and functional fitness.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline FVC (Forced Vital Capacity) (L) at 12 weeks
Time Frame: 12 weeks
|
Change of FVC (Forced Vital Capacity) will be measured on a computerized Spirometer at the baseline and 12 weeks.
|
12 weeks
|
|
Change from baseline FEV1 (Forced Expiratory Volume in 1 minute)(L) at 12 weeks
Time Frame: 12 weeks
|
Change of Forced Expiratory Volume in 1 second will be measured on a computerized Spirometer at the baseline and 12 weeks.
|
12 weeks
|
|
Change from baseline TLC (Total Lung Capacity) (L) at 12 weeks
Time Frame: 12 weeks
|
Change of TLC (Total Lung Capacity) (L) will be measured on a computerized Spirometer at the baseline and 12 weeks.
|
12 weeks
|
|
Change from baseline FRC (Functional Residual Capacity) (L) at 12 weeks
Time Frame: 12 weeks
|
Change of FRC (Functional Residual Capacity) (L) will be measured on a computerized Spirometer at the baseline and 12 weeks.
|
12 weeks
|
|
Change from baseline IC (Inspiratoy Capacity) (L) at 12 weeks
Time Frame: 12 weeks
|
Change of IC (Inspiratoy Capacity) (L) will be measured on a computerized Spirometer at the baseline and 12 weeks.
|
12 weeks
|
|
Change from baseline RV (Residual Volume) (L) at 12 weeks
Time Frame: 12 weeks
|
Change of RV (Residual Volume) (L) will be measured on a computerized Spirometer at the baseline and 12 weeks.
|
12 weeks
|
|
Change from baseline MVV (Maximum Voluntary Ventilation) (L/min) at 12 weeks
Time Frame: 12 weeks
|
Change of MVV (Maximum Voluntary Ventilation) (L/min) will be measured on a computerized Spirometer at the baseline and 12 weeks.
|
12 weeks
|
|
Change from baseline PEFR (Peak Expiratory Flow Rate) (L/sec) at 12 weeks
Time Frame: 12 weeks
|
Change of MVV (Maximum Voluntary Ventilation) (L/sec) will be measured on a computerized Spirometer at the baseline and 12 weeks.
|
12 weeks
|
|
Change from baseline DLCO (Diffusion capacity to carbon monoxide) (ml/mmHg/min) at 12 weeks
Time Frame: 12 weeks
|
Change of DLCO (Diffusion capacity to carbon monoxide) (ml/mmHg/min) will be measured on a computerized Spirometer at the baseline and 12 weeks.
|
12 weeks
|
|
Change from baseline PI max (Maximal Inspiratoy Pressure) (cm H2O) at 12 weeks
Time Frame: 12 weeks
|
Change of PI max (Maximal Inspiratoy Pressure) (cm H2O) will be measured on a computerized Spirometer at the baseline and 12 weeks.
|
12 weeks
|
|
Change from baseline PE max (Maximal Expiratoy Pressure) (cm H2O) at 12 weeks
Time Frame: 12 weeks
|
Change of PE max (Maximal Expiratoy Pressure) (cm H2O) will be measured on a computerized Spirometer at the baseline and 12 weeks.
|
12 weeks
|
|
Change from baseline FEV1/FVC % predicted at 12 weeks
Time Frame: 12 weeks
|
Change of FEV1/FVC % Predicted (Percent Predicted of ratio of FEV1 and FVC) (% predicted) will be measured on a computerized Spirometer at the baseline and 12 weeks.
|
12 weeks
|
|
Change from baseline lower body strength assessed with Chair Standing test at 12 weeks
Time Frame: 12 weeks
|
Change from baseline lower body strength assessed with Chair standing test.
( time/30 sec)
|
12 weeks
|
|
Change from baseline upper body strength assessed with Arm curl test at 12 weeks
Time Frame: 12 weeks
|
Change from baseline upper body strength assessed with Arm curl test (time/30 sec)
|
12 weeks
|
|
Change from baseline lower body flexibility assessed with Chair Sit and Reach test at 12 weeks
Time Frame: 12 weeks
|
Change from baseline lower body flexibility assessed with Chair Sit and Reach test (cm)
|
12 weeks
|
|
Change from baseline upper body flexibility assessed with Back Scratch test at 12 weeks
Time Frame: 12 weeks.
|
Change from baseline upper body flexibility assessed with Back Scratch test (cm)
|
12 weeks.
|
|
Change from baseline agility/dynamic balance assessed with 8-foot Up and Go test at 12 weeks
Time Frame: 12 weeks
|
Change from baseline agility/dynamic balance assessed with 8-foot Up and Go test (sec)
|
12 weeks
|
|
Change from baseline Exercise Capacity assessed with 6-minute walk test at 12 weeks
Time Frame: 12 weeks
|
Change from baseline Exercise Capacity assessed with 6-minute walk test (meter)
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline Dyspnea score assessed with visual analog scale at 12 weeks
Time Frame: 12 weeks
|
Dyspnea or shortness of breath will be measured by visual analog scale (VAS) 1-10 point scale at the baseline and 12 weeks.
|
12 weeks
|
|
Change from baseline Quality of life score assessed with St. George's respiratory Questionnaires (SGRQ) at 12 weeks.
Time Frame: 12 weeks
|
Change from baseline Quality of Life score assessed with St. George's respiratory Questionnaires (SGRQ) in Thai version at 12 weeks.
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Amornpan Ajjimaporn, Ph.D, Mahidol
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 7, 2016
Primary Completion (Anticipated)
October 30, 2019
Study Completion (Anticipated)
October 30, 2019
Study Registration Dates
First Submitted
April 20, 2016
First Submitted That Met QC Criteria
May 10, 2016
First Posted (Estimate)
May 12, 2016
Study Record Updates
Last Update Posted (Actual)
August 16, 2019
Last Update Submitted That Met QC Criteria
August 14, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MU-CIRB 2015/133.2808
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
University of LeicesterUniversity Hospitals, Leicester; University of StrathclydeRecruitingChronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Lung Disease | Chronic Obstructive Airway DiseaseUnited Kingdom
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Modified Dantien Salee Yoga Training Program
-
Maharishi Markendeswar University (Deemed to be...Not yet recruitingPolycystic Ovary Syndrome | Anti-Mullerian Hormone Deficiency | Female Infertility EndocrineIndia
-
Khyber Medical University PeshawarCompleted
-
Ankara UniversityNot yet recruitingCoping Skills | Resilience | Violence Against Women (VAW) | Laughter Yoga | Intimate Partner Violence (IPV)
-
Kaohsiung Medical University Chung-Ho Memorial...Completed
-
China Medical University HospitalRecruitingAnterior Cruciate Ligament ReconstructionTaiwan
-
Istanbul Medipol University HospitalCompletedBronchiectasis AdultTurkey (Türkiye)
-
Ahmed AlshimyCompleted